-
11.发明授权公开(公告)号：US11248031B2
公开(公告)日：2022-02-15
申请号：US16455990
申请日：2019-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US20190099506A1
公开(公告)日：2019-04-04
申请号：US16148604
申请日：2018-10-01
Applicant: Bristol-Myers Squibb Company
Inventor： Michael J. Smith , Haiying Tang , Paul E. Morin , Harold J. Malone
Abstract: Deuterated polymer-biomolecule conjugates and the synthesis and use of deuterated polymer-biomolecule conjugates for detecting the location of specific molecules, e.g., cell surface molecules, in a subject, and for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
-
公开(公告)号：US10221438B2
公开(公告)日：2019-03-05
申请号：US15363724
申请日：2016-11-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
IPC: A61K38/00 , A61K47/62 , A61K47/64 , C07K14/50 , C07K14/78 , C12N15/62 , C12P21/00 , C07K14/435 , C07K14/575
Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
公开(公告)号：US20190055321A1
公开(公告)日：2019-02-21
申请号：US16103654
申请日：2018-08-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, JR. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
IPC: C07K16/46
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
公开(公告)号：US09540424B2
公开(公告)日：2017-01-10
申请号：US14552823
申请日：2014-11-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukerjee , Simeon I. Taylor
IPC: A61K38/00 , C07K14/435 , A61K47/48 , C07K14/78 , C12N15/62 , C07K14/50 , C07K14/575
CPC classification number: C12P21/005 , A61K38/00 , A61K47/62 , A61K47/643 , C07K14/435 , C07K14/50 , C07K14/575 , C07K14/78 , C07K2319/70 , C12N15/62
Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Abstract translation: 本发明涉及基于结合血清白蛋白的第十纤连蛋白III型结构域（10Fn3）的抗体样蛋白。 本发明还涉及包含与用于诊断和治疗应用的异源蛋白质连接的血清白蛋白结合10Fn3的融合分子。
-
Patent Agency Ranking
公开(公告)号：US11623013B2
公开(公告)日：2023-04-11
申请号：US17093941
申请日：2020-11-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael J. Smith , Haiying Tang , Paul E. Morin , Harold J. Malone , Luciano Mueller
Abstract: Deuterated polymer-biomolecule conjugates and the synthesis and use of deuterated polymer-biomolecule conjugates for detecting the location of specific molecules, e.g., cell surface molecules, in a subject, and for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
-
17.发明申请公开(公告)号：US20220185856A1
公开(公告)日：2022-06-16
申请号：US17555633
申请日：2021-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US11344639B2
公开(公告)日：2022-05-31
申请号：US16305284
申请日：2017-05-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , David Donnelly , Dasa Lipovsek , Jochem Gokemeijer , Maria Jure-Kunkel , David Fabrizio , Martin C. Wright , Douglas Dischino , Samuel J. Bonacorsi, Jr. , Ralph Adam Smith , Virginie Lafont , Daniel Cohen , David K. Leung
Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US10406251B2
公开(公告)日：2019-09-10
申请号：US15529260
申请日：2015-11-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , David Donnelly , Dasa Lipovsek , Jochem Gokemeijer , Maria N. Jure-Kunkel , David Fabrizio , Martin C. Wright , Douglas Dischino , Samuel J. Bonacorsi, Jr. , Ralph Adam Smith , Virginie Lafont , Daniel Cohen
IPC: A61K51/08 , C07K14/78 , G01N33/60 , G01N33/68 , G01N33/574
Abstract: Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US20190256570A1
公开(公告)日：2019-08-22
申请号：US16287342
申请日：2019-02-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.035 seconds)
